{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:22:32Z","timestamp":1793503352378,"version":"4.5.0"},"reference-count":111,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,2,21]]},"abstract":"<jats:sec id=\"ab-jrv230001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Malignant primary brain tumors cause more than 15\u202f000 deaths per year in the United States. The annual incidence of primary malignant brain tumors is approximately 7 per 100\u202f000 individuals and increases with age. Five-year survival is approximately 36%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230001-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Approximately 49% of malignant brain tumors are glioblastomas, and 30% are diffusely infiltrating lower-grade gliomas. Other malignant brain tumors include primary central nervous system (CNS) lymphoma (7%) and malignant forms of ependymomas (3%) and meningiomas (2%). Symptoms of malignant brain tumors include headache (50%), seizures (20%-50%), neurocognitive impairment (30%-40%), and focal neurologic deficits (10%-40%). Magnetic resonance imaging before and after a gadolinium-based contrast agent is the preferred imaging modality for evaluating brain tumors. Diagnosis requires tumor biopsy with consideration of histopathological and molecular characteristics. Treatment varies by tumor type and often includes a combination of surgery, chemotherapy, and radiation. For patients with glioblastoma, the combination of temozolomide with radiotherapy improved survival when compared with radiotherapy alone (2-year survival, 27.2% vs 10.9%; 5-year survival, 9.8% vs 1.9%; hazard ratio [HR], 0.6 [95% CI, 0.5-0.7];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). In patients with anaplastic oligodendroglial tumors with 1p\/19q codeletion, probable 20-year overall survival following radiotherapy without vs with the combination of procarbazine, lomustine, and vincristine was 13.6% vs 37.1% (80 patients; HR, 0.60 [95% CI, 0.35-1.03];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.06) in the EORTC 26951 trial and 14.9% vs 37% in the RTOG 9402 trial (125 patients; HR, 0.61 [95% CI, 0.40-0.94];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02). Treatment of primary CNS lymphoma includes high-dose methotrexate-containing regimens, followed by consolidation therapy with myeloablative chemotherapy and autologous stem cell rescue, nonmyeloablative chemotherapy regimens, or whole brain radiation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230001-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The incidence of primary malignant brain tumors is approximately 7 per 100\u202f000 individuals, and approximately 49% of primary malignant brain tumors are glioblastomas. Most patients die from progressive disease. First-line therapy for glioblastoma is surgery followed by radiation and the alkylating chemotherapeutic agent temozolomide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2023.0023","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T11:14:40Z","timestamp":1676978080000},"page":"574","source":"Crossref","is-referenced-by-count":1308,"title":["Glioblastoma and Other Primary Brain Malignancies in Adults"],"prefix":"10.1001","volume":"329","author":[{"given":"Lauren R.","family":"Schaff","sequence":"first","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Neurology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo K.","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Neurology, Weill Cornell Medicine, New York, New York"},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Pharmacology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"jrv230001r1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018.","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"jrv230001r2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumours of the Central Nervous System: a summary.","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"jrv230001r3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"26","key":"jrv230001r4","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"jrv230001r5","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors.","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv230001r6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"issue":"9","key":"jrv230001r7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma.","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"issue":"8","key":"jrv230001r8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/neuonc\/nov069","article-title":"Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States.","volume":"17","author":"Kshettry","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"jrv230001r9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s11912-022-01260-w","article-title":"Ependymoma: evaluation and management updates.","volume":"24","author":"Rud\u00e0","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"jrv230001r10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/oxfordjournals.aje.a009154","article-title":"Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls.","volume":"145","author":"Wrensch","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"11","key":"jrv230001r11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/noz123","article-title":"Risk factors for childhood and adult primary brain tumors.","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"issue":"18","key":"jrv230001r12","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-19-0032","article-title":"Genomic correlates of disease progression and treatment response in prospectively characterized gliomas.","volume":"25","author":"Jonsson","year":"2019","journal-title":"Clin Cancer Res"},{"key":"jrv230001r13","doi-asserted-by":"publisher","first-page":"17267","DOI":"10.1038\/srep17267","article-title":"Quantifying the heritability of glioma using genome-wide complex trait analysis.","volume":"5","author":"Kinnersley","year":"2015","journal-title":"Sci Rep"},{"issue":"11","key":"jrv230001r14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/neuonc\/nos208","article-title":"Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.","volume":"14","author":"Braganza","year":"2012","journal-title":"Neuro Oncol"},{"issue":"5","key":"jrv230001r16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jnci\/djac043","article-title":"Do cell phones cause brain tumors? another piece of the puzzle.","volume":"114","author":"Weed","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"jrv230001r17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/djac042","article-title":"Cellular telephone use and the risk of brain tumors: update of the UK Million Women Study.","volume":"114","author":"Sch\u00fcz","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"jrv230001r18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/1055-9965.EPI-15-0847","article-title":"Approaching a scientific consensus on the association between allergies and glioma risk: a report from the Glioma International Case-Control Study.","volume":"25","author":"Amirian","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"jrv230001r19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/aje\/kwi119","article-title":"History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls.","volume":"161","author":"Wrensch","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"1","key":"jrv230001r20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-019-03208-w","article-title":"Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.","volume":"144","author":"Kaulen","year":"2019","journal-title":"J Neurooncol"},{"issue":"4","key":"jrv230001r21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1468-2982.2009.01970.x","article-title":"Headache attributed to intracranial tumours: a prospective cohort study.","volume":"30","author":"Valentinis","year":"2010","journal-title":"Cephalalgia"},{"issue":"24","key":"jrv230001r22","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019.","volume":"5","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"19","key":"jrv230001r23","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","article-title":"Mutant IDH1 and seizures in patients with glioma.","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"jrv230001r24","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/neuonc\/nov095","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials.","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"jrv230001r25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrclinonc.2017.171","article-title":"Surgical oncology for gliomas: the state of the art.","volume":"15","author":"Sanai","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"jrv230001r26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma.","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"7697","key":"jrv230001r27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours.","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"issue":"5","key":"jrv230001r28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5858\/arpa.2021-0295-CP","article-title":"Molecular biomarker testing for the diagnosis of diffuse gliomas.","volume":"146","author":"Brat","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"jrv230001r29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0959-8049(97)00374-2","article-title":"Prevalence and prognostic significance of epilepsy in patients with gliomas.","volume":"34","author":"Lote","year":"1998","journal-title":"Eur J Cancer"},{"issue":"11","key":"jrv230001r30","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","article-title":"SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.","volume":"23","author":"Walbert","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"jrv230001r31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/neuonc\/now190","article-title":"Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.","volume":"19","author":"Avila","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"jrv230001r33","doi-asserted-by":"publisher","first-page":"E607","DOI":"10.1093\/neuros\/nyz186","article-title":"Letter: when less is more: dexamethasone dosing for brain tumors.","volume":"85","author":"Lim-Fat","year":"2019","journal-title":"Neurosurgery"},{"issue":"10","key":"jrv230001r34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"jrv230001r35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11864-020-00771-7","article-title":"Optimal management of corticosteroids in patients with intracranial malignancies.","volume":"21","author":"Dixit","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"jrv230001r36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-021-03791-x","article-title":"Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma.","volume":"154","author":"Saito","year":"2021","journal-title":"J Neurooncol"},{"key":"jrv230001r37","doi-asserted-by":"publisher","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma.","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro Oncol"},{"issue":"8","key":"jrv230001r38","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/ene.v29.8","article-title":"Venous thromboembolic events in glioblastoma patients: an epidemiological study.","volume":"29","author":"Eisele","year":"2022","journal-title":"Eur J Neurol"},{"issue":"15","key":"jrv230001r39","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1001\/archinte.160.15.2327","article-title":"Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis.","volume":"160","author":"Iorio","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9","key":"jrv230001r40","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.","volume":"8","author":"Perry","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"jrv230001r41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/neuonc\/noab198","article-title":"Management of venous thromboembolism in high-grade glioma: does low molecular weight heparin increase intracranial bleeding risk?","volume":"24","author":"Jo","year":"2022","journal-title":"Neuro Oncol"},{"issue":"2","key":"jrv230001r42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv230001r43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism.","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv230001r44","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D).","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"jrv230001r45","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/neuonc\/noac125","article-title":"Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: a retrospective cohort study.","volume":"24","author":"Reed-Guy","year":"2022","journal-title":"Neuro Oncol"},{"key":"jrv230001r46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2021.10.023","article-title":"Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.","volume":"208","author":"Lee","year":"2021","journal-title":"Thromb Res"},{"issue":"5","key":"jrv230001r47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/onco.13698","article-title":"Safety of direct oral anticoagulants in central nervous system malignancies.","volume":"26","author":"Swartz","year":"2021","journal-title":"Oncologist"},{"key":"jrv230001r48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma.","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb Res"},{"issue":"6","key":"jrv230001r49","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"jrv230001r50","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"jrv230001r51","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"jrv230001r52","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis.","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"jrv230001r53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma.","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"issue":"5","key":"jrv230001r54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"issue":"5","key":"jrv230001r55","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"jrv230001r56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma.","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv230001r57","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial.","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol"},{"issue":"11","key":"jrv230001r58","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma.","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv230001r59","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"jrv230001r60","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"issue":"15","key":"jrv230001r61","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly.","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"issue":"35","key":"jrv230001r62","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International atomic energy agency randomized phase iii study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme.","volume":"33","author":"Roa","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"jrv230001r63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"jrv230001r64","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10103","key":"jrv230001r65","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.","volume":"390","author":"van den Bent","year":"2017","journal-title":"Lancet"},{"issue":"29","key":"jrv230001r66","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma.","volume":"38","author":"Bell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"jrv230001r67","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma.","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"jrv230001r68","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors.","volume":"40","author":"Lassman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv230001r69","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"jrv230001r70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"jrv230001r71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma.","volume":"JCO2200164","author":"Tsien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"30","key":"jrv230001r72","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.21.02166","article-title":"Balancing risk and efficiency in drug development for rare and challenging tumors: a new paradigm for glioma.","volume":"40","author":"Mellinghoff","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9861","key":"jrv230001r73","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"jrv230001r74","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"35","key":"jrv230001r75","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF Inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study.","volume":"36","author":"Kaley","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv230001r76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"jrv230001r77","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma.","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"issue":"22","key":"jrv230001r78","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease.","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"jrv230001r79","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial.","author":"Omuro","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7","key":"jrv230001r80","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial.","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"jrv230001r81","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"jrv230001r82","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"jrv230001r83","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47? for residual or recurrent glioblastoma: a phase 2 trial.","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"26","key":"jrv230001r84","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma.","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv230001r85","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus.","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"jrv230001r86","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac207","article-title":"Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.","author":"Miller","year":"2022","journal-title":"Neuro Oncol"},{"key":"jrv230001r87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.002","article-title":"Evidence-based recommendations on categories for extent of resection in diffuse glioma.","volume":"149","author":"Karschnia","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5897","key":"jrv230001r88","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme.","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"issue":"29","key":"jrv230001r89","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma.","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"jrv230001r90","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial.","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7854","key":"jrv230001r91","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma.","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"issue":"32","key":"jrv230001r92","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study.","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9700","key":"jrv230001r93","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"jrv230001r94","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"jrv230001r95","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study.","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"key":"jrv230001r96","doi-asserted-by":"publisher","DOI":"10.1002\/hon.v41.1","article-title":"Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: a systematic review and meta-analysis.","author":"Epperla","year":"2022","journal-title":"Hematol Oncol"},{"issue":"5","key":"jrv230001r97","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma.","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol"},{"issue":"2","key":"jrv230001r98","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-019-03104-3","article-title":"Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes.","volume":"142","author":"Islim","year":"2019","journal-title":"J Neurooncol"},{"issue":"3","key":"jrv230001r99","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11060-021-03923-3","article-title":"Stereotactic radiosurgery versus active surveillance for asymptomatic, skull-based meningiomas: an international, multicenter matched cohort study.","volume":"156","author":"Mantziaris","year":"2022","journal-title":"J Neurooncol"},{"issue":"11","key":"jrv230001r100","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas.","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"jrv230001r101","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cncr.v124.4","article-title":"Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma.","volume":"124","author":"Rydzewski","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"jrv230001r102","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series.","volume":"109","author":"Lou","year":"2012","journal-title":"J Neurooncol"},{"issue":"1","key":"jrv230001r103","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab.","volume":"109","author":"Nayak","year":"2012","journal-title":"J Neurooncol"},{"issue":"1","key":"jrv230001r104","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"key":"jrv230001r105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: phase ii trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations.","volume":"JCO2102371","author":"Brastianos","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv230001r106","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results.","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro Oncol"},{"key":"jrv230001r107","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00190","article-title":"Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.","volume":"2018","author":"Dunn","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"jrv230001r108","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","article-title":"The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.","volume":"133","author":"Pajtler","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"4","key":"jrv230001r109","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/neuonc\/nox166","article-title":"EANO guidelines for the diagnosis and treatment of ependymal tumors.","volume":"20","author":"Rud\u00e0","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"jrv230001r110","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000339320","article-title":"Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007.","volume":"39","author":"Amirian","year":"2012","journal-title":"Neuroepidemiology"},{"key":"jrv230001r111","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).","author":"Hoang-Xuan","year":"2022","journal-title":"Neuro Oncol"},{"key":"jrv230001r15","unstructured":"International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization. Non-ionizing radiation: static and extremely low-frequency (ELF) electric and magnetic fields. 2002. Accessed February 1, 2023.? https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans\/Non-ionizing-Radiation-Part-1-Static-And-Extremely-Low-frequency-ELF-Electric-And-Magnetic-Fields-2002"},{"key":"jrv230001r32","unstructured":"National Comprehensive Cancer Network. Central Nervous System Cancers Version1. June 2, 2022. Accessed July 16,2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2801673\/jama_schaff_2023_rv_230001_1676478916.46365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T11:14:47Z","timestamp":1676978087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2801673"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":111,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,2,21]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.0023","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}